ArticleDiscover oncology2025
Integrating multi-omics data and machine learning to identify endocrine disrupting chemicals targeting key ccRCC-related genes.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is a highly aggressive and metastatic malignancy that poses a serious threat to patient health. While its development involves both genetic and environmental influences, the interactions between genetic susceptibility and endocrine-disrupting chemicals (EDCs) remain poorly understood. In this study, we integrated multi-omics datasets and applied machine learning approaches to identify EDCs and their associated target genes implicated in ccRCC pathogenesis. We analyzed bulk and single-cell RNA sequencing data and evaluated 101 machine learning algorithms to construct a robust prognostic model. This analysis identified 8 EDCs potentially involved in ccRCC: Diethylnitrosamine, Diethylstilbestrol, Resveratrol, 4,4'-diaminodiphenylmethane, Trichloroethylene, Arsenic, Lead, and 2,3,5-(triglutathion-S-yl)hydroquinone. 5 EDC-associated prognostic genes-BIRC5, CCND1, RRM2, CDH1, and TRIB3-were also identified. Pathway enrichment and immune infiltration analyses revealed intricate interactions between these genes and the tumor microenvironment. Furthermore, cell-cell communication analysis revealed distinct signaling patterns among EDC-associated subpopulations, offering new insights into how EDCs may modulate gene expression and contribute to ccRCC progression. This study provides a foundation for future investigations into EDC-driven tumor biology and may guide the development of targeted therapies and preventative strategies against ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.